|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF622 |
Gene summary for ZNF622 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF622 | Gene ID | 90441 |
| Gene name | zinc finger protein 622 | |
| Gene Alias | ZPR9 | |
| Cytomap | 5p15.1 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q969S3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 90441 | ZNF622 | LZE4T | Human | Esophagus | ESCC | 1.98e-11 | 4.82e-01 | 0.0811 |
| 90441 | ZNF622 | LZE7T | Human | Esophagus | ESCC | 5.90e-09 | 5.04e-01 | 0.0667 |
| 90441 | ZNF622 | LZE8T | Human | Esophagus | ESCC | 4.53e-04 | 1.10e-01 | 0.067 |
| 90441 | ZNF622 | LZE20T | Human | Esophagus | ESCC | 7.88e-08 | 3.00e-01 | 0.0662 |
| 90441 | ZNF622 | LZE24T | Human | Esophagus | ESCC | 1.85e-06 | 2.06e-01 | 0.0596 |
| 90441 | ZNF622 | LZE6T | Human | Esophagus | ESCC | 4.19e-06 | 3.48e-01 | 0.0845 |
| 90441 | ZNF622 | P1T-E | Human | Esophagus | ESCC | 1.64e-12 | 6.21e-01 | 0.0875 |
| 90441 | ZNF622 | P2T-E | Human | Esophagus | ESCC | 4.85e-21 | 2.14e-01 | 0.1177 |
| 90441 | ZNF622 | P4T-E | Human | Esophagus | ESCC | 3.68e-30 | 6.35e-01 | 0.1323 |
| 90441 | ZNF622 | P5T-E | Human | Esophagus | ESCC | 9.91e-29 | 6.31e-01 | 0.1327 |
| 90441 | ZNF622 | P8T-E | Human | Esophagus | ESCC | 2.98e-27 | 7.16e-01 | 0.0889 |
| 90441 | ZNF622 | P9T-E | Human | Esophagus | ESCC | 1.67e-13 | 3.45e-01 | 0.1131 |
| 90441 | ZNF622 | P10T-E | Human | Esophagus | ESCC | 1.62e-24 | 5.17e-01 | 0.116 |
| 90441 | ZNF622 | P11T-E | Human | Esophagus | ESCC | 2.02e-25 | 8.95e-01 | 0.1426 |
| 90441 | ZNF622 | P12T-E | Human | Esophagus | ESCC | 2.00e-23 | 5.09e-01 | 0.1122 |
| 90441 | ZNF622 | P15T-E | Human | Esophagus | ESCC | 8.25e-19 | 3.02e-01 | 0.1149 |
| 90441 | ZNF622 | P16T-E | Human | Esophagus | ESCC | 4.80e-12 | 2.28e-01 | 0.1153 |
| 90441 | ZNF622 | P17T-E | Human | Esophagus | ESCC | 1.99e-14 | 6.89e-01 | 0.1278 |
| 90441 | ZNF622 | P19T-E | Human | Esophagus | ESCC | 9.85e-08 | 8.05e-01 | 0.1662 |
| 90441 | ZNF622 | P20T-E | Human | Esophagus | ESCC | 1.43e-20 | 5.20e-01 | 0.1124 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004225428 | Skin | cSCC | ribosome biogenesis | 206/4864 | 299/18723 | 3.33e-55 | 1.04e-51 | 206 |
| GO:009719329 | Skin | cSCC | intrinsic apoptotic signaling pathway | 150/4864 | 288/18723 | 1.76e-21 | 3.34e-19 | 150 |
| GO:004227328 | Skin | cSCC | ribosomal large subunit biogenesis | 57/4864 | 72/18723 | 4.90e-21 | 8.53e-19 | 57 |
| GO:000697929 | Skin | cSCC | response to oxidative stress | 184/4864 | 446/18723 | 8.57e-13 | 4.89e-11 | 184 |
| GO:006219729 | Skin | cSCC | cellular response to chemical stress | 138/4864 | 337/18723 | 1.10e-09 | 4.23e-08 | 138 |
| GO:003459928 | Skin | cSCC | cellular response to oxidative stress | 117/4864 | 288/18723 | 3.37e-08 | 8.95e-07 | 117 |
| GO:0008631111 | Skin | cSCC | intrinsic apoptotic signaling pathway in response to oxidative stress | 29/4864 | 45/18723 | 6.53e-08 | 1.64e-06 | 29 |
| GO:003109825 | Skin | cSCC | stress-activated protein kinase signaling cascade | 92/4864 | 247/18723 | 5.78e-05 | 5.74e-04 | 92 |
| GO:005140325 | Skin | cSCC | stress-activated MAPK cascade | 88/4864 | 239/18723 | 1.32e-04 | 1.20e-03 | 88 |
| GO:007030225 | Skin | cSCC | regulation of stress-activated protein kinase signaling cascade | 74/4864 | 195/18723 | 1.50e-04 | 1.33e-03 | 74 |
| GO:0036473111 | Skin | cSCC | cell death in response to oxidative stress | 41/4864 | 95/18723 | 2.02e-04 | 1.68e-03 | 41 |
| GO:003287225 | Skin | cSCC | regulation of stress-activated MAPK cascade | 72/4864 | 192/18723 | 2.76e-04 | 2.22e-03 | 72 |
| GO:000725423 | Skin | cSCC | JNK cascade | 60/4864 | 167/18723 | 2.77e-03 | 1.56e-02 | 60 |
| GO:003367425 | Skin | cSCC | positive regulation of kinase activity | 148/4864 | 467/18723 | 3.00e-03 | 1.66e-02 | 148 |
| GO:004632823 | Skin | cSCC | regulation of JNK cascade | 49/4864 | 133/18723 | 3.64e-03 | 1.95e-02 | 49 |
| GO:0022613113 | Thyroid | PTC | ribonucleoprotein complex biogenesis | 292/5968 | 463/18723 | 3.24e-44 | 2.05e-40 | 292 |
| GO:0042254113 | Thyroid | PTC | ribosome biogenesis | 202/5968 | 299/18723 | 3.47e-37 | 5.47e-34 | 202 |
| GO:0006979113 | Thyroid | PTC | response to oxidative stress | 234/5968 | 446/18723 | 6.97e-20 | 9.77e-18 | 234 |
| GO:0097193113 | Thyroid | PTC | intrinsic apoptotic signaling pathway | 164/5968 | 288/18723 | 9.17e-19 | 1.09e-16 | 164 |
| GO:0062197113 | Thyroid | PTC | cellular response to chemical stress | 180/5968 | 337/18723 | 1.36e-16 | 1.16e-14 | 180 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ZNF622 | COR | Oral cavity | Healthy | KRBOX1,CLTA,INTS6, etc. | 1.14e-01 |  |
| ZNF622 | SMC | Oral cavity | ADJ | HMOX1,HPCAL1,SLC7A11, etc. | 4.02e-01 |  |
| ZNF622 | PERI | Oral cavity | LP | HMOX1,HPCAL1,SLC7A11, etc. | 1.08e-01 |  |
| ZNF622 | SMC | Oral cavity | LP | HMOX1,HPCAL1,SLC7A11, etc. | 2.20e-01 | |
| ZNF622 | MESC | Stomach | CAG with IM | SH3D21,PMAIP1,SEC16B, etc. | 3.81e-02 |  |
| ZNF622 | MESC | Stomach | GC | SH3D21,PMAIP1,SEC16B, etc. | 7.22e-02 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF622 | SNV | Missense_Mutation | c.1301G>A | p.Ser434Asn | p.S434N | Q969S3 | protein_coding | tolerated(0.37) | benign(0.275) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF622 | SNV | Missense_Mutation | novel | c.859G>A | p.Asp287Asn | p.D287N | Q969S3 | protein_coding | tolerated(0.07) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ZNF622 | SNV | Missense_Mutation | c.365G>A | p.Ser122Asn | p.S122N | Q969S3 | protein_coding | tolerated(0.48) | benign(0) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| ZNF622 | SNV | Missense_Mutation | c.476T>C | p.Val159Ala | p.V159A | Q969S3 | protein_coding | tolerated(1) | benign(0) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| ZNF622 | SNV | Missense_Mutation | c.1357N>A | p.Ser453Thr | p.S453T | Q969S3 | protein_coding | deleterious(0) | possibly_damaging(0.76) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| ZNF622 | SNV | Missense_Mutation | c.391N>A | p.Ala131Thr | p.A131T | Q969S3 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
| ZNF622 | SNV | Missense_Mutation | rs777954248 | c.1231G>A | p.Ala411Thr | p.A411T | Q969S3 | protein_coding | tolerated(0.4) | benign(0) | TCGA-DM-A0XD-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| ZNF622 | SNV | Missense_Mutation | novel | c.1116G>T | p.Lys372Asn | p.K372N | Q969S3 | protein_coding | deleterious(0.04) | possibly_damaging(0.756) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| ZNF622 | SNV | Missense_Mutation | c.786N>A | p.Ser262Arg | p.S262R | Q969S3 | protein_coding | tolerated(0.52) | benign(0.145) | TCGA-AG-A01Y-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| ZNF622 | SNV | Missense_Mutation | rs774703876 | c.1181N>A | p.Arg394His | p.R394H | Q969S3 | protein_coding | deleterious(0) | possibly_damaging(0.719) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |